安罗替尼联合T P化疗方案治疗老年非小细胞肺癌患者的效果

Effects of Anlotinib combined with TP chemotherapy regimen in treatment of elderly patients with non-small cell lung cancer

目的:观察安罗替尼联合TP化疗方案治疗老年非小细胞肺癌(NSCLC)患者的效果。方法:选取68例老年NSCLC患者作为研究对象,应用随机数字表法分为对照组和研究组各34例。对照组予以TP化疗方案治疗,研究组在对照组基础上给予安罗替尼治疗,比较两组治疗前后糖类抗原125(CA125)水平、肺腺癌转移相关转录因子1(MALAT1)水平、临床控制率和不良反应发生率。结果:治疗后,研究组CA125和MALAT1水平均低于对照组,差异有统计学意义(P<0.05);研究组临床控制率为73.53%(25/34),高于对照组的47.06%(16/34),差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:安罗替尼联合TP化疗方案治疗老年NSCLC患者可降低CA125和MALAT1水平,提高临床控制率,效果优于单纯TP化疗方案治疗。

Objective:To observe effects of Anlotinib combined with TP chemotherapy regimen in treatment of elderly patients with nonsmall cell lung cancer(NSCLC).Methods:68 elderly patients with NSCLC were selected as the research objects,and were divided into control group and study group by using the random number table method,34 cases in each group.The control group was treated with TP chemotherapy,while the study group was treated with Anlotinib on the basis of that of the control group.The levels of carbohydrate antigen 125(CA125)and lung adenocarcinoma metastasis-related transcription factor 1(MALAT1)levels,the clinical control rate and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the levels of CA125 and MALAT1 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The clinical control rate of the study group was 73.53%(25/34),which was higher than the control group of 47.06%(16/34),and the difference was statistically significant(P<0.05).However,there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Anlotinib combined with TP chemotherapy in the treatment of the elderly NSCLC patients can reduce the levels of CA125 and MALAT1 and improve the clinical control rate.Moreover,it is superior to single TP chemotherapy.